COST-EFFECTIVENESS ANALYSIS OF DIMETHYL FUMARATE IN THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS IN ITALY

被引：0

作者：

Mantovani, L. G. ^{[1
]}

Furneri, G. ^{[2
]}

Cortesi, P. A. ^{[1
]}

Puma, E. ^{[3
]}

Santoni, L. ^{[3
]}

Prosperini, L. ^{[4
]}

机构：

[1] Univ Milano Bicocca, Milan, Italy

[2] EBMA Consulting SRL, Melegnano, Italy

[3] Biogen, Milan, Italy

[4] S Camillo Forlanini Hosp, Rome, Italy

来源：

VALUE IN HEALTH | 2019年 / 22卷

关键词：

D O I：

暂无

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

PND24

引用

下载

页码：S740 / S741

页数：2

共 50 条

[31] Cost-effectiveness analysis of escalating to natalizumab or switching among immunomodulators in relapsing-remitting multiple sclerosis in Italy
Furneri, Gianluca
Santoni, Laura
Ricella, Chiara
Prosperini, Luca
BMC HEALTH SERVICES RESEARCH, 2019, 19 (1)
[32] Cost-effectiveness analysis of escalating to natalizumab or switching among immunomodulators in relapsing-remitting multiple sclerosis in Italy
Gianluca Furneri
Laura Santoni
Chiara Ricella
Luca Prosperini
BMC Health Services Research, 19
[33] Safety and persistence of dimethyl fumarate as a treatment for relapsing-remitting multiple-sclerosis
Boullosa-Lale, Silvia
Gonzalez-Freire, Lara
Martinez-Martinez, Luciano
Crespo-Diz, Carlos
FARMACIA HOSPITALARIA, 2021, 45 (02) : 73 - 76
[34] COST-EFFECTIVENESS ANALYSIS OF CLADRIBINE TABLETS FOR TREATMENT OF PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS IN BULGARIA
Djambazov, S.
Slavchev, G.
Dineva, T.
Panayotov, P.
Vekov, T.
VALUE IN HEALTH, 2018, 21 : S206 - S206
[35] Cost-Effectiveness Analysis of Peginterferon Beta-1a in the Treatment of Relapsing-Remitting Multiple Sclerosis in Italy: Results of an Updated Analysis
Centonze, Diego
Iannazzo, Sergio
Santoni, Laura
Saleri, Cecilia
Puma, Elisa
Giuliani, Luigi
Canonico, Pier Luigi
FARMECONOMIA-HEALTH ECONOMICS AND THERAPEUTIC PATHWAYS, 2018, 19 (01) : 47 - 52
[36] Budget impact analysis of delayed-release dimethyl-fumarate in the treatment of relapsing-remitting multiple sclerosis in Italy
Furneri, Gianluca
Marchesi, Chiara
Santoni, Laura
FARMECONOMIA-HEALTH ECONOMICS AND THERAPEUTIC PATHWAYS, 2016, 17 (01) : 29 - 39
[37] A COST-EFFECTIVENESS ANALYSIS OF FINGOLIMOD VERSUS DIMETHYL FUMARATE AS A SECOND-LINE DISEASE MODIFYING TREATMENT IN PATIENTS WITH HIGHLY ACTIVE RELAPSING-REMITTING MULTIPLE SCLEROSIS
Raikou, M.
Kalogeropoulou, M.
Rombopoulos, G.
VALUE IN HEALTH, 2015, 18 (07) : A758 - A758
[38] COST-EFFECTIVENESS OF ESCALATING TO NATALIZUMAB OR SWITCHING AMONG IMMUNOMODULATORS IN RELAPSING-REMITTING MULTIPLE SCLEROSIS IN ITALY
Furneri, G.
Santoni, L.
Ricella, C.
Prosperini, L.
VALUE IN HEALTH, 2015, 18 (07) : A695 - A695
[39] COST-EFFECTIVENESS OF NATALIZUMAB IN PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS IN RUSSIA
Matveev, N., V
Sabanov, A., V
Luneva, A., V
VALUE IN HEALTH, 2014, 17 (03) : A60 - A60
[40] Cost-Effectiveness of Fingolimod in Treating Patients With Relapsing-Remitting Multiple Sclerosis
Agashivala, Neetu V.
Dastani, Homa B.
Carlton, Rashad
Sarnes, Evelyn
AMERICAN JOURNAL OF PHARMACY BENEFITS, 2011, 3 (06) : 320 - 328

← 1 2 3 4 5 →